Epitope-based peptide vaccine design and target site characterization against novel coronavirus disease caused by SARS-CoV-2
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
The outbreak of the 2019 novel coronavirus (SARS-CoV-2) has infected thousands of people with a large number of deaths across 26 countries. The sudden appearance of the virus leads to the limited existing therapies for SARS-CoV-2. Therefore, vaccines and antiviral medicines are in desperate need. This study took immune-informatics approaches to identify B- and T-cell epitopes for surface glycoprotein (S) of SARS-CoV-2, followed by estimating their antigenicity and interactions with the human leukocyte antigen (HLA) alleles. We identified four B cell epitopes, two MHC class-I and nine MHC class-II binding T-cell epitopes, which showed highly antigenic features. Allergenicity, toxicity and physiochemical properties analysis confirmed the specificity and selectivity of epitopes. The stability and safety of epitopes were confirmed by digestion analysis. No mutations were observed in all the selected B- and T-cell epitopes across all isolates from different locations worldwide. Epitopes were thus identified and some of them can be potential candidates for vaccine development.
Article activity feed
-
SciScore for 10.1101/2020.02.25.965434: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources Data retrieval and structural analysis: Primary sequence of SARS-CoV-2 protein was retrieved from NCBI database using accession number MN908947.3 [3]. NCBIsuggested: (NCBI, RRID:SCR_006472)Protein sequence was analyzed for its chemicals and physical properties including GRAVY (Grand average of hydropathicity), half-life, molecular weight, stability index and amino acid atomic composition via an online tool Protparam [13] Protparamsuggested: (ProtParam Tool, RRID:SCR_018087)TMHMM v2.0 (http://www.cbs.dtu.dk/services/TMHMM/) was applied to examine the transmembrane topology of S protein. http:/…SciScore for 10.1101/2020.02.25.965434: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources Data retrieval and structural analysis: Primary sequence of SARS-CoV-2 protein was retrieved from NCBI database using accession number MN908947.3 [3]. NCBIsuggested: (NCBI, RRID:SCR_006472)Protein sequence was analyzed for its chemicals and physical properties including GRAVY (Grand average of hydropathicity), half-life, molecular weight, stability index and amino acid atomic composition via an online tool Protparam [13] Protparamsuggested: (ProtParam Tool, RRID:SCR_018087)TMHMM v2.0 (http://www.cbs.dtu.dk/services/TMHMM/) was applied to examine the transmembrane topology of S protein. http://www.cbs.dtu.dk/services/TMHMM/suggested: (TMHMM Server, RRID:SCR_014935)Existence of disulphide-bonds were examined through an online tool DIANNA v1.1 which uses trained neural system to make predictions [15]. DIANNAsuggested: (DiANNA, RRID:SCR_018529)Pymol was used to examine the positions of selected linear and discontinuous epitopes on the 3D structure of SARS-CoV-2 protein. Pymolsuggested: (PyMOL, RRID:SCR_000305)The antigenicity score of each epitope was calculated by VaxiJen v2.0. VaxiJensuggested: (VaxiJen, RRID:SCR_018514)The phylogenetic tree of the S proteins with mutations were generated using MEGA software [23]. MEGAsuggested: (Mega BLAST, RRID:SCR_011920)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
